Liver fibrosis as a barometer of systemic health by gauging the risk of extrahepatic disease
Metabolism and Target Organ Damage,
Journal Year:
2024,
Volume and Issue:
4(4)
Published: Nov. 15, 2024
This
review
article
proposes
the
theory
that
liver
fibrosis,
abnormal
accumulation
of
excessive
extracellular
matrix,
is
not
just
an
indicator
disease
but
also
a
negative
reflection
overall
systemic
health.
Liver
fibrosis
poses
heavy
financial
burden
on
healthcare
systems
worldwide
and
can
develop
due
to
chronic
from
various
causes,
often
sustained
inflammation.
may
generate
symptoms
become
apparent
only
when
it
reaches
stage
cirrhosis
associated
with
clinically
significant
portal
hypertension
leads
decompensation
events
or
promotes
development
hepatocellular
carcinoma.
While
viral
hepatitis
alcohol
consumption
were
once
primary
causes
featuring
this
role
now
increasingly
taken
over
by
metabolic
dysfunction-associated
steatotic
(MASLD).
In
MASLD,
endothelial
dysfunction
essential
component
in
pathogenesis,
promoting
present
cells
other
organs
such
as
heart,
lungs,
kidneys.
Accordingly,
predictor
liver-related
outcomes,
well
all-cause
mortality,
cardiovascular
risk,
extrahepatic
cancer.
Physicians
should
be
aware
individuals
seeking
medical
attention
for
reasons
unrelated
health
have
advanced
fibrosis.
Early
identification
these
at-risk
lead
more
comprehensive
assessment
use
treatment
options,
both
approved
investigational,
slow
reverse
progression
Language: Английский
Liver-Kidney-Metabolic Health, Sex, and Menopause Impact Total Scores and Monovessel vs. Multivessel Coronary Artery Calcification
Advances in Therapy,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 14, 2025
Language: Английский
Cardiovascular Mortality in MASLD: A Matter of Fat. Caution in Interpreting Liver Fat Quantification in Populations With High Fibrosis Variability
Liver international communications.,
Journal Year:
2025,
Volume and Issue:
6(1)
Published: Feb. 18, 2025
Language: Английский
Red cell distribution width/platelet ratio predicts decompensation of metabolic dysfunction-associated steatotic liver disease-related compensated advanced chronic liver disease
World Journal of Gastroenterology,
Journal Year:
2024,
Volume and Issue:
31(3)
Published: Dec. 17, 2024
Prognostication
of
compensated
advanced
chronic
liver
disease
(cACLD)
is
paramount
importance
for
the
physician-and-patient
communication
and
rational
clinical
decisions.
The
paper
published
by
Dallio
et
al
reports
on
red
cell
distribution
width
(RDW)/platelet
ratio
(RPR)
as
a
non-invasive
biomarker
in
predicting
decompensation
metabolic
dysfunction-associated
steatotic
(MASLD)-related
cACLD.
Differently
from
other
biomarkers
algorithms,
RPR
inexpensive
widely
available,
based
parameters
which
are
included
complete
blood
count.
computed
grounds
two
different
items,
one
which,
RDW,
mirrors
host's
response
to
variety
stimuli
non-specific.
second
parameter
involved
RPR,
platelet
count,
more
specific
has
been
used
hepatological
clinic
discriminate
cirrhotic
non-cirrhotic
decades.
Cardiovascular
primary
cause
mortality
among
MASLD
subjects,
followed
extra-hepatic
cancers
liver-related
mortality.
Therefore,
should
be
validated
not
only
terms
events
but
also
prediction
major
adverse
cardiovascular
cancers.
Adequately
sized
multi-ethnic
confirmatory
investigation
required
define
role
significance
stratification
MASLD-cACLD.
Language: Английский
MASLD: predictive value for liver-related events and extra-hepatic complications
Expert Review of Gastroenterology & Hepatology,
Journal Year:
2024,
Volume and Issue:
unknown, P. 1 - 4
Published: Dec. 1, 2024
KEYWORDS:
Cardiovascular
diseasecomputed
tomographyliver-related
eventsmagnetic
resonanceMASH;
MASLDprognosticationrisk
stratificationultrasonography
Language: Английский